IL-3 Treatment of Jak3-Deficient Mice Increased the Proportion of Peripheral CD4+ and CD8+ T Cells and B220+IgM+ B Cells
| Experimental Group . | Average Percentage of Positive Splenocytes . | ||
|---|---|---|---|
| CD4+ . | CD8+ . | B220+IgM+ . | |
| Jak3+/+ | 7.9 (±3.1) | 3.0 (±0.4) | 40.1 (±6.2) |
| Jak3−/− | 0.4 (±0.1) | 0.3 (±0.2) | 1.0 (±0.3) |
| Jak3−/− (IL-3 treatment) | 1.6 (±0.2) | 1.0 (±0.8) | 4.9 (±1.5) |
| Experimental Group . | Average Percentage of Positive Splenocytes . | ||
|---|---|---|---|
| CD4+ . | CD8+ . | B220+IgM+ . | |
| Jak3+/+ | 7.9 (±3.1) | 3.0 (±0.4) | 40.1 (±6.2) |
| Jak3−/− | 0.4 (±0.1) | 0.3 (±0.2) | 1.0 (±0.3) |
| Jak3−/− (IL-3 treatment) | 1.6 (±0.2) | 1.0 (±0.8) | 4.9 (±1.5) |
In 4 independent experiments, splenocytes from individual mice (2 to 4 mice in each group) were pooled and analyzed. The average percentage of splenocytes positive (±SD) for each set of phenotypic markers is shown.